Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Truist Securities raised its price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $205.00 from $200.00 on Thursday, while maintaining a Buy rating on the stock. The company, currently valued at $7.54 billion, appears undervalued according to InvestingPro analysis, with analysts maintaining a strong buy consensus rating of 1.44.
The price target increase follows Jazz’s webcast highlighting the commercial strategy for its recently approved drug Modeyso (dordaviprone), which treats an ultra-rare form of aggressive glioma with H3 K27M mutation.
Truist Securities noted that the lack of competition for this high unmet need brain tumor positions Modeyso for "robust commercial uptake" in the market.
The firm also pointed out that Jazz Pharmaceuticals received a Priority Review Voucher (PRV) for the approval, which has an estimated market value exceeding $150 million.
Truist’s model update reflects Modeyso’s wholesale acquisition cost (WAC) and duration of therapy based on clinical data, factors that contributed to the price target adjustment.
In other recent news, Jazz Pharmaceuticals reported its second-quarter earnings for 2025, which showed a wider-than-expected loss per share of -8.25, compared to the anticipated -7.62. Despite this, the company’s revenue slightly surpassed forecasts, reaching $1.05 billion. In addition to its earnings report, Jazz Pharmaceuticals officially launched Modeyso/dordaviprone for recurrent H3 K27M-mutant diffuse midline glioma, a rare pediatric brain tumor. Stifel reiterated its Buy rating and set a price target of $230.00, highlighting Modeyso as the first approved treatment for this condition. RBC Capital also responded positively to Jazz Pharmaceuticals’ developments, raising its price target to $151.00 from $145.00 and maintaining an Outperform rating. These updates follow an investor call discussing the recently approved drug Modeyso, which treats rare H3 K27M mutant gliomas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.